Not available
Quote | Seres Therapeutics Inc. (NASDAQ:MCRB)
Last: | $0.7311 |
---|---|
Change Percent: | -3.8% |
Open: | $0.75 |
Close: | $0.76 |
High: | $0.7858 |
Low: | $0.7222 |
Volume: | 2,029,224 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Seres Therapeutics Inc. (NASDAQ:MCRB)
Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medically vulnerable patient populations Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiom...
2024-03-05 15:33:08 ET Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript March 05, 2024, 08:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege ...
Message Board Posts | Seres Therapeutics Inc. (NASDAQ:MCRB)
Subject | By | Source | When |
---|---|---|---|
$MCRB Perverse mkt action now. Candidate passed PDUFA | MiamiGent | investorshub | 04/28/2023 5:29:25 PM |
ARNA did that in the past- an offering | MiamiGent | investorshub | 04/28/2023 5:28:18 PM |
Why would they use debt financing rather than | Cosa | investorshub | 04/27/2023 7:48:05 PM |
$MCRB Another comment from another forum | MiamiGent | investorshub | 04/27/2023 3:38:53 PM |
. | MiamiGent | investorshub | 04/27/2023 3:19:40 PM |
News, Short Squeeze, Breakout and More Instantly...
Seres Therapeutics Inc. Company Name:
MCRB Stock Symbol:
NASDAQ Market:
Seres Therapeutics Inc. Website:
Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medically vulnerable patient populations Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiom...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts ...